Advanced Search

 

Study ID Status Title Patient Level Data
115677 Completed A Two-Part, Open-label, Sequential, Double Cohort, Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Rosuvastatin when Co administered with Darapladib in Healthy Adult Subjects Study Listed on ClinicalStudyDataRequest.com
115678 Completed An open-label, single-sequence study to evaluate the potential CYP 3A4 pharmacokinetic interaction of Darapladib (SB-480848) in healthy subjects Study Listed on ClinicalStudyDataRequest.com
115774 Completed An Open-Label, Non-Randomized, Two-Period, Cross-Over, Mass Balance Study to Investigate the Recovery, Excretion and Pharmacokinetics of 14C-GSK2140944 Administered as a Single Intravenous and Single Oral Dose to Healthy Adult Male Subjects (BTZ115774) Study Listed on ClinicalStudyDataRequest.com
115805 Completed A 12-Week Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate /Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once-Daily via a Novel Dry Powder Inhaler Compared with Tiotropium Bromide Inhalation Powder 18mcg Delivered Once-Daily via the HandiHaler in Subjects with Chronic Obstructive Pulmonary Disease (COPD) Who Have or Are at Risk for Co-morbid Cardiovascular Disease Study Listed on ClinicalStudyDataRequest.com
115812 Completed An open label Phase IIIb study to evaluate efficacy and safety of Ambrisentan in Chinese patients with pulmonary arterial hypertension (PAH)
115879 Completed A Phase II Multicenter, Parallel-Group, Randomized, Dose-Ranging Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Following 12 Weeks of Oral Administration of GSK2336805 With Pegylated Interferon and Ribavirin in Treatment-Naïve Subjects With Chronic Genotype 1 or 4 Hepatitis C Infection Study Listed on ClinicalStudyDataRequest.com
115919 Terminated An adaptive Phase II study to evaluate the efficacy, pharmacodynamics, safety and tolerability of GSK2586184 in patients with mild to moderate systemic lupus erythematosus Study Listed on ClinicalStudyDataRequest.com
115921 Completed A Double-blind, Randomised, Placebo-controlled Study to Investigate the Efficacy and Safety of Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis in Subjects Receiving Standard of Care Therapy
115927 Completed Special Drug Use Investigation for ROTARIX
115938 Completed A multi-center, randomized, double-blind, dose-ranging study to evaluate GSK573719 in combination with fluticasone furoate, fluticasone furoate alone, and an active control of fluticasone furoate/vilanterol combination in subjects with asthma Study Listed on ClinicalStudyDataRequest.com
115983 Completed Rechallenge Analysis: Detection of Potential Drug-Induced Liver Injury using Kaiser California Database
116008 Completed A randomized, placebo-controlled, study to evaluate the effects of GSK1278863A on pulmonary artery pressure in healthy volunteers Study Listed on ClinicalStudyDataRequest.com
116010 Completed A Phase I, Open-label, Three-Period, Single Sequence, Crossover Study Evaluating the Drug-Drug Interaction Between Eltrombopag and Boceprevir and Between Eltrombopag and Telaprevir in Healthy Adult Subjects
116059 Completed Prostate Cancer in Benign prostatic hyperplasia (BPH) patients
116073 Completed To evaluate the pharmacokinetics, safety and tolerability of Retosiban (GSK221149) co-administered with EFAVIRENZ Study Listed on ClinicalStudyDataRequest.com
116086 Terminated A pharmacy based open study to evaluate whether pack size affects compliance for subjects diagnosed with diabetes type II who are established on metformin treatment Study Listed on ClinicalStudyDataRequest.com
116099 Completed A 4-Week, Phase II, Randomized, Double-Blind, Dose-Ranging, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Japanese Hemodialysis-Dependent Subjects with Anemia Associated with Chronic Kidney Disease Study Listed on ClinicalStudyDataRequest.com
116100 Completed A multicenter, open-label study to evaluate preventive efficacy for herpes simplex virus infection and safety of 256U87 (valaciclovir hydrochloride) in adult and pediatric hematopoietic stem cell transplantation patients Study Listed on ClinicalStudyDataRequest.com
116108 Completed A Single-Dose, Randomised, Open-Label, Two-Period Crossover Study to Determine the Bioequivalence of the Second Generation Dutasteride and Tamsulosin HCl Combination Capsule in the Fed State in Healthy Adult Male Subjects
116119 Completed An open label, randomized, parallel, single dose study to investigate safety and pharmacokinetics following intravenous administration and subcutaneous administration of GSK1550188 in healthy Japanese males Study Listed on ClinicalStudyDataRequest.com
116132 Completed A Randomized, Double-Blind, 3-Way, Cross-Over Study to Evaluate Lung Function Response after Treatment with Umeclidinium 62.5 mcg, Vilanterol 25 mcg, and Umeclidinium/Vilanterol 62.5/25 mcg Once-Daily in Subjects with Chronic Obstructive Pulmonary Disease (COPD) Study Listed on ClinicalStudyDataRequest.com
116133 Completed A Randomized, Double-Blind, 3-Way, Cross-Over Study to Evaluate Lung Function Response after Treatment with Umeclidinium 62.5mcg, Vilanterol 25mcg, and Umeclidinium/Vilanterol 62.5/25mcg Once-Daily in Subjects with Chronic Obstructive Pulmonary Disease (COPD) Study Listed on ClinicalStudyDataRequest.com
116134 Completed DB2116134: A Randomized, Multi-center, Double-blind, Double-dummy, Parallel Group Study to Evaluate the Efficacy and Safety of Umeclidinium bromide/Vilanterol Compared with Fluticasone propionate/Salmeterol Over 12 weeks in Subjects with COPD Study Listed on ClinicalStudyDataRequest.com
116135 Completed A multicenter, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of the addition of umeclidinium bromide (62.5mcg) once-daily to fluticasone propionate/salmeterol (250/50mcg) twice-daily, umeclidinium bromide (125mcg) once-daily to fluticasone propionate/salmeterol (250/50mcg) twice-daily versus placebo to fluticasone propionate/salmeterol (250/50mcg) twice-daily over 12 weeks with COPD Study Listed on ClinicalStudyDataRequest.com
116136 Completed A multicenter, randomized, double-blind, parallelgroup study to evaluate the efficacy and safety of the addition of umeclidinium bromide Inhalation Powder (62.5mcg) once-daily to fluticasone propionate/salmeterol (250/50mcg) twice-daily, umeclidinium bromide Inhalation Powder (125mcg) once-daily to fluticasone propionate/salmeterol (250/50mcg) twice-daily versus placebo to fluticasone propionate/salmeterol (250/50mcg) twice-daily over 12 weeks in subjects with COPD. Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.